[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Exact Sciences Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100561372","falcon-real-world-evidence-registry-100561372",false,"NCT06589310","Falcon Real World Evidence Registry","Falcon - The Exact Sciences Multicancer Early Detection (MCED) Real World Evidence (RWE) Registry","Inclusion Criteria:\n\n* Participant age at time of consent is between 50 and 80 years\n* Agree to receive the Exact Sciences MCED test and follow-up imaging\n* Willing and able to provide informed consent\n* Access to a suitable technology and willing to complete surveys electronically\n\nExclusion Criteria:\n\n* Any invasive tumor (excluding non-melanoma skin cancers) or hematological malignancy in the previous three years or current suspicion of cancer and\u002For in active treatment (e.g., chemotherapy, radiation therapy, immunotherapy, and\u002For surgery",true,"ALL","50 Years","80 Years",{"count":21,"type":22},25000,"ESTIMATED","OBSERVATIONAL","This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.",[26],"Cancer","RECRUITING","2026-05-20",{"date":30,"type":31},"2026-05-22","ACTUAL",{"date":33,"type":31},"2024-08-01",{"date":35,"type":22},"2031-01",{"name":37,"class":38},"Exact Sciences Corporation","INDUSTRY",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100634822","endometrial-cancer-vaginal-fluid-specimen-collection-study-100634822","NCT07544680","Endometrial Cancer Vaginal Fluid Specimen Collection Study","Endometrial Cancer Vaginal Fluid Specimen Collection Study: \"ENVISION\"","ENVISION","Inclusion Criteria\n\nCohort 1 Participants:\n\n* Age ≥ 45 years, OR age ≥ 18 years with at least one risk factor\n* Diagnosed with abnormal uterine bleeding (AUB)\n* Planning standard-of-care endometrial tissue sampling to assess for endometrial cancer (EC) or atypical endometrial hyperplasia\u002Fendometrial intraepithelial neoplasia (AEH\u002FEIN)\n\nCohort 2 Participants:\n\n* Age ≥ 18 years\n* Newly diagnosed, biopsy-confirmed EC or AEH\u002FEIN\n* Planning initial management for their endometrial pathology\n\nExclusion Criteria\n\n* Prior partial or complete hysterectomy\n* Current pregnancy\n* Prior pelvic or vaginal radiotherapy\n* Chemotherapy within past 5 years (except tamoxifen)\n* Any condition judged by the Investigator to preclude participation\n\nAdditional for Cohort 1:\n\n* Cancer diagnosis within past 5 years (except non-gynecologic skin cancer)\n* Current biopsy-proven cervical, vaginal, or vulvar cancer, or lower genital tract dysplasia\n* Current biopsy-proven endometrial cancer, hyperplasia, or benign polyp\n* Benign endometrial biopsy within last month\n\nAdditional for Cohort 2:\n\n* Cancer diagnosis other than EC within past 5 years (except non-gynecologic skin cancer)\n* Prior cervical cancer or biopsy-proven cervical dysplasia\n* Surgery for recurrent EC\n* Preoperative neoadjuvant chemotherapy or radiotherapy for current EC\n* Prior treatment or surgery to remove target pathology during current episode","FEMALE","18 Years",{"count":51,"type":22},4200,"This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.",[54,55,56,57,58],"Abnormal Uterine Bleeding (AUB)","Endometrial Cancer","Atypical Endometrial Hyperplasia","Endometrial Hyperplasia With Atypia","Endometrial Intraepithelial Neoplasia",[54,60,61,62,63,64,65,66,67,68],"Endometrial Cancer (EC)","Atypical Endometrial Hyperplasia (AEH)","Endometrial Hyperplasia with Atypia","Endometrial Intraepithelial Neoplasia (EIN)","Precancerous Conditions","Post-Menopausal Bleeding","Specimen Collection","Sample Collection","in vitro diagnostic (IVD) devices","2026-04-15",{"date":71,"type":31},"2026-04-22",{"date":73,"type":31},"2026-03-10",{"date":75,"type":22},"2028-04-24",{"name":37,"class":38},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100546934","exactdna-003--nsabp-b-64-study-of-molecular-residual-disease-detection-in-breast-cancer-mrd-100546934","NCT06401421","EXActDNA-003 \u002F NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)","EXActDNA-003 \u002F NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease","Inclusion Criteria:\n\n1. The participant or a legally authorized representative must provide study-specific informed consent prior to study entry.\n2. The participant must be ≥ 18 years of age.\n3. ECOG performance status 0 or 1.\n4. Histologically confirmed invasive carcinoma of the breast.\n5. Planned neoadjuvant therapy which includes cytotoxic chemotherapy.\n6. Tumor size ≥ 2.1 cm in greatest diameter.\n7. Unifocal or multifocal cancer documented to be the same histologic clinical subtype.\n8. Clinically node positive or if node negative, any one of the following:\n\n   1. TNBC or HER2+ subtype\n   2. HR+\u002FHER2-negative with at least one of the following:\n\n   i. High tumor grade (G3) ii. Ki67 index of 20% or higher iii. High genomic risk (Oncotype DX® (ODX) Breast Recurrence Score of \\> 25, MammaPrint® High, etc.)\n9. Willing and able to comply with the study requirements, which includes the collection of a total of 34 cc (2.5 Tablespoons) of blood for each research blood draw.\n10. Available residual tissue from diagnostic biopsy from the breast or an involved ipsilateral lymph node for submission to create a bespoke ctDNA assay.\n\nExclusion Criteria:\n\n1. Definitive clinical or radiologic evidence of metastatic disease.\n2. Initiated neoadjuvant therapy for current breast cancer diagnosis.\n3. Synchronous diagnosis of another invasive cancer, other than this breast cancer, except for non-melanoma skin cancers.\n4. Completed all therapy (including endocrine therapy) \\\u003C5 years ago for any previous invasive solid organ malignancy (with exception of non-melanoma skin cancers) including prior breast cancer. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment.\n5. Completed all therapy for any previous hematologic malignancy \\\u003C 5 years ago.\n6. Multicentric or contralateral invasive breast cancers.\n7. Known pregnancy at time of enrollment.\n8. Prior solid organ transplant.\n9. Prior allogeneic hematopoietic stem cell transplant.",{"count":86,"type":22},1800,"The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.\n\nParticipants will be followed for up to 5.5 years.",[89],"Breast Cancer",[89,91],"ctDNA","2026-01-16",{"date":94,"type":31},"2026-01-20",{"date":96,"type":31},"2024-06-07",{"date":98,"type":22},"2030-04",{"name":37,"class":38},58,""]